translocations or amplifications on top of the genomic alterations currently present in the first CLL, but deficiency the prevalent mutations noticed in Principal DLBCL indicating that they might correspond to a different Organic classification.Unfit patients also have the choice of venetoclax plus obinutuzumab (VO) as frontline therapy. This is ba